Blocking DNA Repair Enzyme Reduces Cancer ecDNA
The research-stage finding in cancer cell lines points to polymerase θ as a possible target against drug-resistant tumors.
Updated on Nov. 6, 2026 in Life Sciences

Researchers report that polymerase θ-dependent microhomology-mediated end joining repairs DNA breaks on extrachromosomal DNA (ecDNA) in cancer cells, and that inhibiting this repair pathway reduces ecDNA abundance. The findings were published in Nature Genetics on November 6, 2026, and are research-stage, not an available therapy.
Why it matters
ecDNA frequently carries amplified oncogenes and contributes to tumor evolution and drug resistance, so a repair pathway that sustains it is a candidate target. The work also points to FANCM as a factor in ecDNA stability, extending the search for vulnerabilities beyond chromosomal DNA.
The evidence comes from experiments in cancer cell lines plus genome-wide mapping of damage sites, with the comparison being disruption of three separate repair pathways. Inhibiting polymerase θ reduced ecDNA abundance while disrupting the other two did not, but the extraction gives no quantitative effect sizes, and it remains unclear how broadly the result holds across tumor types.
The players
Nature Genetics
A peer-reviewed journal in genetics research that published the study.
FANCM
A DNA repair protein that resolves transcription-induced DNA secondary structures and was implicated in ecDNA stability in this study.
The details
Extrachromosomal DNA is a circular piece of DNA that floats outside the chromosomes and can be copied many times, often carrying cancer-driving genes. The study found that when breaks occur on these circles, a repair process called microhomology-mediated end joining, which relies on the enzyme polymerase θ, stitches them back together. Breaks tend to form at TA dinucleotide repeats, stretches of the two DNA bases thymine and adenine, where transcription, the copying of DNA into RNA, creates stress; the protein FANCM normally resolves these structures, and when that fails, polymerase θ repair takes over.
Timeline
November 6, 2026: study published in Nature Genetics.
The Tech Race
Polymerase θ is being pursued as a DNA repair target in cancer research, and this study adds ecDNA as a context where its inhibition has measurable effects. The work also identifies FANCM as a factor in ecDNA stability, which could expand the set of candidate targets that researchers test against these circular DNA elements.
This is research-stage work in cancer cell lines, and no timeline for clinical testing or availability was announced. Patients will not be affected by this finding until it has been tested in animal models and human trials, which the extraction does not describe.
The takeaway
The core insight is that cancer cells rely on specific repair pathways to keep ecDNA intact, which makes those pathways candidate targets. Watch for follow-up studies testing polymerase θ inhibition in animal models and for any published effect sizes that would show how strongly ecDNA abundance falls.
Further reading
For broader context on the cellular machinery behind these findings, explore our Life Sciences coverage.
Source note: This article includes information reported by Nature.


